Document Detail


TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit.
MedLine Citation:
PMID:  16318869     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Hypofibrinolysis, at least in part due to high levels of plasminogen activator inhibitor-1 (PAI-1), has been reported to occur frequently in patients with coronary artery disease (CAD). A recently described carboxypeptidase, thrombin-activatable fibrinolysis inhibitor (TAFI), is involved in the regulation of the balance between coagulation and fibrinolysis. High TAFI plasma levels may therefore contribute to a hypofibrinolytic state and to an increased risk for thrombotic disorders. There are contradictory results regarding TAFI levels in CAD patients, possibly because the characteristics of patients investigated and the time of blood sampling were different among different studies. MATERIALS AND METHODS: Fibrinolytic inhibitors (TAFI activity, TAFI antigen and PAI-1 activity plasma levels) were measured in 44 consecutive patients admitted to the Coronary Care Unit of the University of Florence and in a group of 44 healthy controls, matched for age and sex, to detect a possible association of their levels with acute CAD. RESULTS: No differences were found in TAFI levels, either activity or antigen, between patients and controls. PAI-1 activity was significant different between patients and controls (p=0.0001). The frequencies of TAFI activity and antigen over cut-off levels were similar in patients and controls. Instead, higher PAI-1 levels were more frequent (p=0.04) in patients respect to controls. The univariate analysis confirmed the association of increased PAI-1 levels with acute CAD [OR=3.3; p=0.04]. Among the patients, TAFI and PAI-1 levels were not different according to clinical presentation of symptoms or indication to immediate percutaneous revascularization. CONCLUSION: Our study suggests that in acute phase of CAD no increased levels of TAFI are detectable in plasma.
Authors:
Anna Paola Cellai; Emilia Antonucci; Agatina Alessandrello Liotta; Sandra Fedi; Rossella Marcucci; Michela Falciani; Cristina Giglioli; Rosanna Abbate; Domenico Prisco
Related Documents :
3400599 - One-year psychosocial follow-up of patients with chest pain and angiographically normal...
11829219 - Initial experience with off-pump coronary artery bypass grafting.
2120309 - Repeat infusion of recombinant tissue-type plasminogen activator in patients with acute...
1149209 - Appraisal of sinus node artery disease.
10501339 - Hla antigens in patients with variant angina in japan.
1622989 - Vascular rejection and its relationship to allograft coronary artery disease.
23459449 - Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients ...
16556669 - Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive ...
10941819 - Lipoprotein(a) and lipids in relation to inflammation in rheumatoid arthritis.
Publication Detail:
Type:  Journal Article     Date:  2005-11-28
Journal Detail:
Title:  Thrombosis research     Volume:  118     ISSN:  0049-3848     ISO Abbreviation:  Thromb. Res.     Publication Date:  2006  
Date Detail:
Created Date:  2006-09-04     Completed Date:  2007-12-12     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0326377     Medline TA:  Thromb Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  495-500     Citation Subset:  IM    
Affiliation:
Department of Medical and Surgical Critical Care, Thrombosis Centre, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Adult
Aged
Aged, 80 and over
Carboxypeptidase U / blood*
Coronary Angiography / methods
Coronary Artery Disease / blood*,  diagnosis,  therapy
Coronary Care Units*
Enzyme Activation
Female
Humans
Male
Middle Aged
Plasminogen Activator Inhibitor 1 / blood*
Chemical
Reg. No./Substance:
0/Plasminogen Activator Inhibitor 1; EC 3.4.17.20/Carboxypeptidase U

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The effects of direct current cardioversion for persistent atrial fibrillation on indices of endothe...
Next Document:  Differences between A 68930 and SKF 82958 could suggest synergistic roles of D1 and D5 receptors.